Several possible studies
Story checked
FDA expert panel endorses Grail's Galleri multi-cancer blood test (opens in a new tab)
statnews.com · 2026-09-23
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
FDA expert panel endorses Grail's Galleri multi-cancer blood test
statnews.com · 2026-09-23
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedAn FDA advisory panel endorsed Grail’s Galleri blood test to screen for multiple types of cancer, concluding that the benefits outweighed the risks.View evidenceHide evidence
As statedbenefits outweighed its risks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedThe panel voted 10 to 0 that there was “reasonable assurance” the test is safe.View evidenceHide evidence
As stated10 to 0
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedThe panel voted 6 to 4 that there was reasonable assurance the test is effective.View evidenceHide evidence
As stated6 to 4
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedThe panel voted 7 to 2 with one abstention that the benefits of Galleri outweigh the risk for use in patients meeting the proposed indication criteria.View evidenceHide evidence
As stated7 to 2 with one abstention
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe FDA is not obliged to follow the panel’s advice, although it often does.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref · 15 candidate papers
Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.
Nature Medicine · 2026 · PubMed
Abstract IA022: Assessing implementation of a multi-cancer early detection blood test for population screening in a clinical practice setting: prospective PATHFINDER cohort study
Cancer Prevention Research · 2023 · Crossref
Early detection of multiple cancers: the era of methylation-based liquid biopsy.
Frontiers in Oncology · 2026 · PubMed
092 Preventing an epidemic of overdiagnosis with multi-cancer early detection tests for cancer screening
092 Preventing an Epidemic of Overdiagnosis with Multi-cancer Early Detection Tests for Cancer Screening · 2025 · Crossref
Case Report: Multi-cancer early detection utilizing blood-based genomics: Single-institution case series of novel cancer screening.
Frontiers in Oncology · 2025 · PubMed
And 10 more candidates considered.